Dirk Schadendorf
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Immunology top 0.02%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
Papers in
- Oncology 522
- Cutaneous Melanoma Detection and Management 201
- Cancer Immunotherapy and Biomarkers 182
- CAR-T cell therapy research 176
-
- Melanoma and MAPK Pathways 265
- vaccines and immunoinformatics approaches 41
- Co-authors
- Reinhard Dummer (147 shared papers)Caroline Robert (115 shared papers)Axel Hauschild (130 shared papers)Antje Sucker (95 shared papers)Selma Ugurel (111 shared papers)Claus Garbe (96 shared papers)Jedd D. Wolchok (29 shared papers)F. Stephen Hodi (52 shared papers)
- Journals
- Journal of Clinical Oncology (147 papers)Annals of Oncology (81 papers)European Journal of Cancer (73 papers)International Journal of Cancer (30 papers)Melanoma Research (26 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Dirk Schadendorf
953 papers receiving 46.6k citations
Dirk Schadendorf's Hit Papers
Peers
Comparison fields: 5 of 196
- Oncology 23.7k
- Immunology 13.7k
- Molecular Biology 18.8k
- Cancer Research 3.7k
- Dermatology 1.9k
Countries citing papers authored by Dirk Schadendorf
This map shows the geographic impact of Dirk Schadendorf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Schadendorf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Schadendorf more than expected).
Fields of papers citing papers by Dirk Schadendorf
This network shows the impact of papers produced by Dirk Schadendorf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Schadendorf. The network helps show where Dirk Schadendorf may publish in the future.
Co-authors
The 25 scholars most cited alongside Dirk Schadendorf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 990 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells Hit paper breakdown → | 1998 | 2381 |
| 2 | Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma Hit paper breakdown → | 2015 | 1571 |
| 3 | TERT Promoter Mutations in Familial and Sporadic Melanoma Hit paper breakdown → | 2013 | 1284 |
| 4 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1071 |
| 5 | Melanoma Hit paper breakdown → | 2018 | 1061 |
| 6 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Hit paper breakdown → | 2018 | 1033 |
| 7 | Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Hit paper breakdown → | 2009 | 939 |
| 8 | Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma Hit paper breakdown → | 2000 | 938 |
| 9 | Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma Hit paper breakdown → | 2017 | 883 |
| 10 | Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Hit paper breakdown → | 2018 | 690 |
| 11 | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study Hit paper breakdown → | 2013 | 501 |
| 12 | Melanoma Hit paper breakdown → | 2015 | 456 |
| 13 | Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma Hit paper breakdown → | 2009 | 417 |
| 14 | 2006 | 411 | |
| 15 | Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2018 | 400 |
| 16 | Metabolic heterogeneity confers differences in melanoma metastatic potential Hit paper breakdown → | 2019 | 369 |
| 17 | 1993 | 348 | |
| 18 | 2006 | 339 | |
| 19 | 2013 | 338 | |
| 20 | 2017 | 313 |
About Dirk Schadendorf
Dirk Schadendorf is a scholar working on Oncology, Molecular Biology, Immunology, Epidemiology and Dermatology, having authored 990 papers that have together received 47.4k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (265 papers), Cutaneous Melanoma Detection and Management (201 papers), Immunotherapy and Immune Responses (196 papers), Cancer Immunotherapy and Biomarkers (182 papers), CAR-T cell therapy research (176 papers), T-cell and B-cell Immunology (45 papers), vaccines and immunoinformatics approaches (41 papers) and Nonmelanoma Skin Cancer Studies (39 papers). The work is most often cited by research in Oncology (23.7k citations), Immunology (13.7k citations), Molecular Biology (18.8k citations), Cancer Research (3.7k citations) and Dermatology (1.9k citations). Dirk Schadendorf has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Reinhard Dummer, Caroline Robert, Axel Hauschild, Antje Sucker, Selma Ugurel, Claus Garbe, Jedd D. Wolchok, F. Stephen Hodi, Yuansheng Sun and Selma Alijagic. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, International Journal of Cancer and Melanoma Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.